Cargando…
Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
The psychedelic alkaloid ibogaine is increasingly used as an oral treatment for substance use disorders, despite being unlicensed in most countries and having reported adverse events. Using wild-type and genetically modified mice, we investigated the impact of mouse (m)Abcb1a/1b and Abcg2 drug efflu...
Autores principales: | F. Martins, Margarida L., Heydari, Paniz, Li, Wenlong, Martínez-Chávez, Alejandra, Venekamp, Nikkie, Lebre, Maria C., Lucas, Luc, Beijnen, Jos H., Schinkel, Alfred H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931498/ https://www.ncbi.nlm.nih.gov/pubmed/35308219 http://dx.doi.org/10.3389/fphar.2022.855000 |
Ejemplares similares
-
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
por: Li, Wenlong, et al.
Publicado: (2021) -
Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022) -
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Wang, Yaogeng, et al.
Publicado: (2021) -
The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
por: Koenig, Xaver, et al.
Publicado: (2015) -
N-(Hydroxymethyl)ibogaine
por: Jarraya, Raoudha Mezghani, et al.
Publicado: (2008)